<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462043</url>
  </required_header>
  <id_info>
    <org_study_id>ND0612-315</org_study_id>
    <nct_id>NCT03462043</nct_id>
  </id_info>
  <brief_title>A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension</brief_title>
  <official_title>A Pivotal, Open-Label, Randomized, Crossover Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroDerm Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroDerm Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the relative bioavailability of s.c. infused ND0612 versus jejunally&#xD;
      infused CLES in patients with advanced PD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be an open-label, randomized, crossover study to assess the relative&#xD;
      bioavailability of s.c. infused ND0612 versus jejunally infused CLES in patients with&#xD;
      advanced PD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Decision to change the study design&#xD;
  </why_stopped>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 20, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>6-7 days</time_frame>
    <description>To assess relative bioavailability of levodopa (LD) administered as ND0612, infused subcutaneously (s.c.), versus LD administered as carbidopa-levodopa enteral suspension (CLES)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Parkinson</condition>
  <arm_group>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>ND0612</intervention_name>
    <description>s.c. infused</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>CLES</intervention_name>
    <description>Carbidopa-Levodopa Enteral Suspension.</description>
    <arm_group_label>Sequence A</arm_group_label>
    <arm_group_label>Sequence B</arm_group_label>
    <arm_group_label>Sequence C</arm_group_label>
    <arm_group_label>Sequence D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Advanced PD treated with LD/CD at a dose of at least 800 mg LD&#xD;
&#xD;
          -  Female patients must have a negative pregnancy test at screening and at admission.&#xD;
&#xD;
          -  Patients must have a body mass index (BMI) within the range of 18.5 - 35 kg/m2, where&#xD;
             BMI = body weight (kg) / height (m2) at screening.&#xD;
&#xD;
          -  Must be willing and able to communicate and participate in the whole study.&#xD;
&#xD;
          -  Must provide written informed consent.&#xD;
&#xD;
          -  Must agree to use an adequate method of contraception (per local independent ethics&#xD;
             committee requirements).&#xD;
&#xD;
          -  Area of administration to be evaluable for local skin reaction (normal skin without&#xD;
             skin burns, scars or large tattoos in the area of administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any relevant medical, surgical, or psychiatric condition, laboratory value, or&#xD;
             concomitant medication which, in the opinion of the Investigator, makes the patient&#xD;
             unsuitable for study entry or potentially unable to complete all aspects of the study.&#xD;
&#xD;
          -  Positive serum serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human&#xD;
             Immunodeficiency Virus (HIV) at the screening visit.&#xD;
&#xD;
          -  Patients with a history of drug abuse or alcoholism within the past 12 months prior to&#xD;
             screening or positive drugs of abuse or alcohol test result at the screening visit&#xD;
             and/or on admission.&#xD;
&#xD;
          -  Clinically significant electrocardiogram (ECG) rhythm abnormalities.&#xD;
&#xD;
          -  Renal or liver dysfunction that may alter drug metabolism including: serum creatinine&#xD;
             &gt;1.5 mg/dL, serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT)&#xD;
             &gt;2 x upper limit of normal (ULN), total serum bilirubin &gt;2.5 mg/dL.&#xD;
&#xD;
          -  Psychiatric, neurological or behavioral disorders that may interfere with the conduct&#xD;
             or interpretation of the study, including dementia, or patients who are considered to&#xD;
             be violent or at suicidal risk by the Investigator.&#xD;
&#xD;
          -  Blood loss of greater than 500 mL within the previous 3 months prior to first dosing.&#xD;
&#xD;
          -  use of any medication from the prohibited concomitant therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osnat Ehrman</last_name>
    <role>Study Director</role>
    <affiliation>NeuroDerm Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>91601</name>
      <address>
        <city>Roma</city>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 6, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>November 20, 2018</last_update_submitted>
  <last_update_submitted_qc>November 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

